Individuals with IBD, especially CD, have an increased risk for myocardial infarction, ischemic heart disease, cerebrovascular accident, and major adverse cardiovascular events.

Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to α4β7 integrin that modulates gut lymphocyte ...

The ACG has published new health maintenance recommendations for patients with IBD, which include appropriate vaccinations, ...

Background The development of IBD is known to involve early immunological alterations, but our understanding of the changes ...

Inflammatory bowel diseases (IBDs) fall into one of two main groups: Crohn's disease (CD) or ulcerative colitis (UC). Both are chronic inflammatory disorders of the gastrointestinal tract ...

Getting beyond the gut: AI tool reveals hidden health risks for people with inflammatory bowel disease by Gillian Rutherford, University of Alberta edited by Lisa Lock, reviewed by Robert Egan ...

Johnson & Johnson Innovative Medicine has announced that the European Commission (EC) has approved a Marketing Authorisation (MA) for two new indications of TREMFYA ® (guselkumab), for the treatment ...

Yale Medicine has more on inflammatory bowel disease. SOURCES: Wolters Kluwer Health, news release, June 4, 2025; Gastroenterology Nursing, May/June 2025 ...

Around 20% of people with IBD have a close relative, such as a parent or sibling, who has had the same disease at some point. Scientists have identified more than 200 genetic mutations linked to ...